サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1720914

三叉神経痛治療の世界市場レポート 2025年

Trigeminal Neuralgia Treatment Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.37円
三叉神経痛治療の世界市場レポート 2025年
出版日: 2025年05月01日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

三叉神経痛治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.7％で9億5,000万米ドルに成長します。予測期間の成長は、ヘルスケア専門家や一般住民の三叉神経痛に対する認知度の向上、TN症例の増加、高齢者の増加、医療費の増加、診断症例数の増加などに起因すると考えられます。主要動向としては、神経調節技術の進歩、調査技術の向上、医療研究と技術の進歩、低侵襲手術技術の採用、デジタルヘルス技術の統合などが挙げられます。

神経疾患の有病率の増加は、今後数年間の三叉神経痛治療市場の拡大を促進すると予想されます。神経疾患には、脳、脊髄、神経を含む神経系に影響を及ぼす疾患が含まれます。遺伝的素因、感染症、外傷、毒素、自己免疫反応、変性など、さまざまな要因がこれらの疾患の有病率上昇に寄与しています。三叉神経痛治療は、激しい顔面痛の緩和、神経刺激の軽減、QOLの向上、疼痛管理、さらなる神経障害の予防により、神経疾患患者を支援します。例えば、2022年4月、ベルギーを拠点とする非営利団体であるEuropean Brain Councilのデータによると、600以上の神経疾患と300近くの精神疾患が、6,500万人のてんかん患者を含む世界中の数百万人に影響を及ぼしています。欧州だけでも1,050万人が認知症であり、2050年には1,870万人に増加すると予測されています。その結果、神経疾患の罹患率の増加が三叉神経痛治療への需要を促進すると予想されます。

三叉神経痛治療市場の主要企業は、規制当局の承認を得て市場でのプレゼンスを拡大するため、治験薬（IND）申請に注力しています。IND申請により、製薬企業は規制当局に承認を求めてヒト臨床検査を開始し、医薬品の安全性、有効性、適切な投与量を評価することができます。例えば、スイスを拠点とする臨床段階のバイオテクノロジー企業であるノエマ・ファーマは、2022年2月、三叉神経痛（TN）を対象としたmGluR5阻害剤NOE-101の第2b相臨床検査を開始するためのIND承認を米国食品医薬品局（FDA）から取得しました。LibraTN検査は、三叉神経痛に関連した疼痛を有する成人を対象に、NOE-101の有効性と安全性を評価する24週間の多施設共同プラセボ対照検査であり、2024年前半に結果が出る予定です。さらにFDAは、バシムグルラント（NOE-101）の開発と薬事審査プロセスを加速させるため、ファスト・トラック指定を行りました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の三叉神経痛治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の三叉神経痛治療市場：成長率分析
  • 世界の三叉神経痛治療市場の実績：規模と成長、2019～2024年
  • 世界の三叉神経痛治療市場の予測：規模と成長、2024～2029年、2034年
  • 世界の三叉神経痛治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の三叉神経痛治療市場：治療タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 医薬品
  • 手術
  • その他の治療タイプ
  • 世界の三叉神経痛治療市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 世界の三叉神経痛治療市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
  • 病院
  • 専門クリニック
  • 外来手術センター
  • その他
  • 世界の三叉神経痛治療市場、医薬品のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 抗けいれん薬
  • 筋弛緩剤
  • 抗うつ薬
  • 世界の三叉神経痛治療市場、手術のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 微小血管減圧手術
  • ガンマナイフ放射線手術
  • 根切断術
  • 世界の三叉神経痛治療市場、その他の治療タイプのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 神経ブロック
  • 定位放射線手術
  • 理学療法

第7章 地域別・国別分析

  • 世界の三叉神経痛治療市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
  • 世界の三叉神経痛治療市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 三叉神経痛治療市場：競合情勢
  • 三叉神経痛治療市場：企業プロファイル
    • Aetna Inc.
    • Thermo Fisher Scientific Inc.
    • Novartis AG
    • Sandoz
    • Sun Pharmaceutical Industries Ltd.

第31章 その他の大手企業と革新的企業

  • Apotex Inc.
  • Lupin Limited
  • Taro Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Kriya Therapeutics
  • Convergence Pharmaceuticals Limited
  • Noema Pharma AG
  • Max Healthcare
  • Initiator Pharma AS
  • Coda BIoTherapeutics Inc.
  • Oxford Cannabinoid Technologies Holdings Plc
  • NanoVibronix
  • Biogen Idec
  • Shanghai SIMR BIoTechnology Co. Ltd.
  • Capnia Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

  • 三叉神経痛治療市場、2029年：新たな機会を提供する国
  • 三叉神経痛治療市場、2029年：新たな機会を提供するセグメント
  • 三叉神経痛治療市場、2029年：成長戦略
    • 市場動向による戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r34173

Trigeminal neuralgia treatment involves medical strategies to manage the severe, sharp facial pain caused by trigeminal neuralgia, which affects the trigeminal nerve. The primary goal of treatment is to alleviate pain, reduce the frequency and intensity of episodes, and address underlying nerve irritation, ultimately improving the patient's quality of life.

The main types of trigeminal neuralgia treatment include medications, surgery, and other therapeutic approaches. Medications are formulated to reduce pain by controlling nerve activity. These treatments are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and are utilized by several end-users, such as hospitals, specialty clinics, and ambulatory surgical centers.

The trigeminal neuralgia treatment market research report is one of a series of new reports from The Business Research Company that provides trigeminal neuralgia treatment market statistics, including the trigeminal neuralgia treatment industry global market size, regional shares, competitors with the trigeminal neuralgia treatment market share, detailed trigeminal neuralgia treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the trigeminal neuralgia treatment industry. This trigeminal neuralgia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The trigeminal neuralgia treatment market size has grown strongly in recent years. It will grow from $0.68 billion in 2024 to $0.73 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to the increasing incidence of chronic diseases, the rising prevalence of neurological disorders and trigeminal neuralgia, the growing demand for minimally invasive treatments, and the increasing preference for minimally invasive surgeries.

The trigeminal neuralgia treatment market size is expected to see strong growth in the next few years. It will grow to $0.95 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to increasing awareness of trigeminal neuralgia among healthcare professionals and the general population, a rise in TN cases, a growing geriatric population, increasing healthcare expenditure, and a higher number of diagnosed cases. Major trends include advancements in neuromodulation techniques, improvements in TENS technology, progress in medical research and technology, the adoption of minimally invasive surgical techniques, and the integration of digital health technologies.

The increasing prevalence of neurological disorders is expected to drive the expansion of the trigeminal neuralgia treatment market in the coming years. Neurological disorders encompass conditions that affect the nervous system, including the brain, spinal cord, and nerves. Various factors contribute to the rising prevalence of these disorders, such as genetic predisposition, infections, trauma, toxins, autoimmune responses, and degeneration. Trigeminal neuralgia treatment helps neurological patients by alleviating severe facial pain, reducing nerve irritation, improving quality of life, managing pain, and preventing further neurological damage. For example, in April 2022, data from the European Brain Council, a Belgium-based non-profit organization, indicated that more than 600 neurological diseases and nearly 300 psychiatric conditions impact millions worldwide, including 65 million people with epilepsy. In Europe alone, 10.5 million individuals have dementia, with projections estimating an increase to 18.7 million by 2050. Consequently, the growing incidence of neurological disorders is expected to fuel the demand for trigeminal neuralgia treatments.

Leading companies in the trigeminal neuralgia treatment market are focusing on investigational new drug (IND) applications to obtain regulatory approvals and expand their market presence. An IND application allows pharmaceutical companies to seek approval from regulatory agencies to begin human clinical trials, assessing a drug's safety, efficacy, and appropriate dosage. For instance, in February 2022, Noema Pharma, a Switzerland-based clinical-stage biotechnology company, received IND approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2b clinical trial for the mGluR5 inhibitor NOE-101 in trigeminal neuralgia (TN). The LibraTN study is a 24-week, multi-center, placebo-controlled trial evaluating the efficacy and safety of NOE-101 in adults experiencing TN-related pain, with results expected in the first half of 2024. Additionally, the FDA granted fast track designation to basimglurant (NOE-101) to accelerate its development and regulatory review process.

In October 2022, Pfizer Inc., a U.S.-based pharmaceutical company, acquired Biohaven Pharmaceuticals for approximately $11.6 billion. This acquisition aims to strengthen Pfizer's neurology portfolio by securing full rights to Biohaven Pharmaceuticals' migraine treatments, including Nurtec ODT (rimegepant) and other CGRP receptor antagonists. The deal enhances Pfizer's leadership in the migraine treatment market while expanding its pipeline of innovative neurological therapies. Biohaven Pharmaceuticals, a U.S.-based pharmaceutical company, has also been involved in researching and developing potential treatments for trigeminal neuralgia, including rimegepant.

Major players in the trigeminal neuralgia treatment market are Aetna Inc., Thermo Fisher Scientific Inc., Novartis AG, Sandoz, Sun Pharmaceutical Industries Ltd., Apotex Inc., Lupin Limited, Taro Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Kriya Therapeutics, Convergence Pharmaceuticals Limited, Noema Pharma AG, Max Healthcare, Initiator Pharma AS, Coda Biotherapeutics Inc., Oxford Cannabinoid Technologies Holdings Plc, NanoVibronix, Biogen Idec, Shanghai SIMR Biotechnology Co. Ltd., Capnia Inc.

North America was the largest region in the trigeminal neuralgia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the trigeminal neuralgia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The trigeminal neuralgia treatment market consists of revenues earned by entities by providing services such as physical therapy, patient education, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The trigeminal neuralgia treatment market also includes sales of anticonvulsants, muscle relaxants, and tricyclic antidepressants (TCAs). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Trigeminal Neuralgia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on trigeminal neuralgia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for trigeminal neuralgia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The trigeminal neuralgia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Treatment Type: Medications; Surgery; Other Treatment Types
  • 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • 3) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Other End-Users
  • Subsegments:
  • 1) By Medications: Anticonvulsants; Muscle Relaxants; Antidepressants
  • 2) By Surgery: Microvascular Decompression Surgery; Gamma Knife Radiosurgery; Rhizotomy
  • 3) By Other Treatment Types: Nerve Blocks; Stereotactic Radiosurgery; Physical Therapy
  • Companies Mentioned: Aetna Inc.; Thermo Fisher Scientific Inc.; Novartis AG; Sandoz; Sun Pharmaceutical Industries Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Trigeminal Neuralgia Treatment Market Characteristics

3. Trigeminal Neuralgia Treatment Market Trends And Strategies

4. Trigeminal Neuralgia Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Trigeminal Neuralgia Treatment Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Trigeminal Neuralgia Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Trigeminal Neuralgia Treatment Market Growth Rate Analysis
  • 5.4. Global Trigeminal Neuralgia Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Trigeminal Neuralgia Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Trigeminal Neuralgia Treatment Total Addressable Market (TAM)

6. Trigeminal Neuralgia Treatment Market Segmentation

  • 6.1. Global Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Medications
  • Surgery
  • Other Treatment Types
  • 6.2. Global Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • 6.3. Global Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Other End-Users
  • 6.4. Global Trigeminal Neuralgia Treatment Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Anticonvulsants
  • Muscle Relaxants
  • Antidepressants
  • 6.5. Global Trigeminal Neuralgia Treatment Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Microvascular Decompression Surgery
  • Gamma Knife Radiosurgery
  • Rhizotomy
  • 6.6. Global Trigeminal Neuralgia Treatment Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Nerve Blocks
  • Stereotactic Radiosurgery
  • Physical Therapy

7. Trigeminal Neuralgia Treatment Market Regional And Country Analysis

  • 7.1. Global Trigeminal Neuralgia Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Trigeminal Neuralgia Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Trigeminal Neuralgia Treatment Market

  • 8.1. Asia-Pacific Trigeminal Neuralgia Treatment Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Trigeminal Neuralgia Treatment Market

  • 9.1. China Trigeminal Neuralgia Treatment Market Overview
  • 9.2. China Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Trigeminal Neuralgia Treatment Market

  • 10.1. India Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Trigeminal Neuralgia Treatment Market

  • 11.1. Japan Trigeminal Neuralgia Treatment Market Overview
  • 11.2. Japan Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Trigeminal Neuralgia Treatment Market

  • 12.1. Australia Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Trigeminal Neuralgia Treatment Market

  • 13.1. Indonesia Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Trigeminal Neuralgia Treatment Market

  • 14.1. South Korea Trigeminal Neuralgia Treatment Market Overview
  • 14.2. South Korea Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Trigeminal Neuralgia Treatment Market

  • 15.1. Western Europe Trigeminal Neuralgia Treatment Market Overview
  • 15.2. Western Europe Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Trigeminal Neuralgia Treatment Market

  • 16.1. UK Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Trigeminal Neuralgia Treatment Market

  • 17.1. Germany Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Trigeminal Neuralgia Treatment Market

  • 18.1. France Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Trigeminal Neuralgia Treatment Market

  • 19.1. Italy Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Trigeminal Neuralgia Treatment Market

  • 20.1. Spain Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Trigeminal Neuralgia Treatment Market

  • 21.1. Eastern Europe Trigeminal Neuralgia Treatment Market Overview
  • 21.2. Eastern Europe Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Trigeminal Neuralgia Treatment Market

  • 22.1. Russia Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Trigeminal Neuralgia Treatment Market

  • 23.1. North America Trigeminal Neuralgia Treatment Market Overview
  • 23.2. North America Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Trigeminal Neuralgia Treatment Market

  • 24.1. USA Trigeminal Neuralgia Treatment Market Overview
  • 24.2. USA Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Trigeminal Neuralgia Treatment Market

  • 25.1. Canada Trigeminal Neuralgia Treatment Market Overview
  • 25.2. Canada Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Trigeminal Neuralgia Treatment Market

  • 26.1. South America Trigeminal Neuralgia Treatment Market Overview
  • 26.2. South America Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Trigeminal Neuralgia Treatment Market

  • 27.1. Brazil Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Trigeminal Neuralgia Treatment Market

  • 28.1. Middle East Trigeminal Neuralgia Treatment Market Overview
  • 28.2. Middle East Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Trigeminal Neuralgia Treatment Market

  • 29.1. Africa Trigeminal Neuralgia Treatment Market Overview
  • 29.2. Africa Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Trigeminal Neuralgia Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Trigeminal Neuralgia Treatment Market Competitive Landscape
  • 30.2. Trigeminal Neuralgia Treatment Market Company Profiles
    • 30.2.1. Aetna Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Sandoz Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Trigeminal Neuralgia Treatment Market Other Major And Innovative Companies

  • 31.1. Apotex Inc.
  • 31.2. Lupin Limited
  • 31.3. Taro Pharmaceutical Industries Ltd.
  • 31.4. Torrent Pharmaceuticals Ltd.
  • 31.5. Kriya Therapeutics
  • 31.6. Convergence Pharmaceuticals Limited
  • 31.7. Noema Pharma AG
  • 31.8. Max Healthcare
  • 31.9. Initiator Pharma AS
  • 31.10. Coda Biotherapeutics Inc.
  • 31.11. Oxford Cannabinoid Technologies Holdings Plc
  • 31.12. NanoVibronix
  • 31.13. Biogen Idec
  • 31.14. Shanghai SIMR Biotechnology Co. Ltd.
  • 31.15. Capnia Inc.

32. Global Trigeminal Neuralgia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Trigeminal Neuralgia Treatment Market

34. Recent Developments In The Trigeminal Neuralgia Treatment Market

35. Trigeminal Neuralgia Treatment Market High Potential Countries, Segments and Strategies

  • 35.1 Trigeminal Neuralgia Treatment Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Trigeminal Neuralgia Treatment Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Trigeminal Neuralgia Treatment Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer